Skip to main content
SYNTARA LIMITED logo

SYNTARA LIMITED — Investor Relations & Filings

Ticker · SNT ISIN · AU0000312480 LEI · 52990054L6XWT345FW20 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,620 across all filing types
Latest filing 2009-06-10 Capital/Financing Update
Country AU Australia
Listing ASX SNT

About SYNTARA LIMITED

https://syntaratx.com.au/

Syntara Limited is a clinical-stage drug development company focused on the discovery and development of novel small molecule therapeutics for inflammatory and fibrotic diseases. The company specializes in the inhibition of amine oxidase enzymes, including lysyl oxidase (LOX) and semicarbazide-sensitive amine oxidase (SSAO). Its primary clinical focus is on hematological malignancies and multi-organ fibrosis. The lead drug candidate, PXS-5505, is a pan-LOX inhibitor currently being evaluated for the treatment of myelofibrosis. Additionally, the company develops treatments for skin scarring, pulmonary fibrosis, and neurodegenerative conditions. Syntara leverages its proprietary drug discovery platform to address significant unmet medical needs through targeted enzymatic inhibition, aiming to modify disease progression in complex pathological environments.

Recent filings

Filing Released Lang Actions
Disclosure Notice Under Section 708A(5)(e) 1 page ?
Capital/Financing Update Classification · 95% confidence The document is a disclosure notice under section 708A(5)(e) of the Corporations Act 2001, relating to the issuance of shares by Pharmaxis Ltd. It details the number of shares issued, compliance with relevant sections of the Corporations Act, and confirms no excluded information is present. The content is a formal regulatory announcement about share issuance without full disclosure, typical of a capital/financing update. The document length is short (1468 characters), and it is not a full financial report but a specific notice about share placement. Therefore, it fits best under Capital/Financing Update (CAP).
2009-06-10 English
Exercise of Employee Options 10 pages ?Kb
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and references ASX rules (2.7, 3.10.3, 3.10.4, 3.10.5), which are Australian Securities Exchange listing rules related to new securities issuance. The content details the issuance of fully paid ordinary shares upon exercise of options under an employee option plan, including number of securities, classes, exercise prices, and dates. It also includes a quotation agreement with ASX and warranties related to the securities issuance and quotation. There are no financial statements or management discussion, nor is this a report or earnings release. The document is a formal announcement of new securities issued and application for quotation on the ASX. This fits the definition of a Share Issue/Capital Change announcement (SHA). The document length is over 14,000 characters, indicating it is a full announcement, not a brief notice or report publication announcement.
2009-06-09 English
Pharmaxis Announces Placement of $47 Million and SPP 2 pages ?Kb
Capital/Financing Update Classification · 95% confidence The document is a media release dated 4 June 2009 announcing Pharmaxis' placement of $47 million through a share placement and a share purchase plan. It details the number of shares issued, pricing, discounts, and the intended use of proceeds for commercial launch activities. There are no financial statements or detailed financial performance data included. The document is an announcement of a capital raising event, specifically a placement and share purchase plan, which fits the category of Capital/Financing Update (CAP). The document length is 4503 characters, which is sufficient for a detailed announcement but does not constitute a full financial report. Therefore, the appropriate classification is CAP with high confidence.
2009-06-03 English
Appendix 3B - Placement 10 pages ?Kb
Capital/Financing Update Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and references ASX listing rules (Rule 2.7, 3.10.3, 3.10.4, 3.10.5). It details the issuance of 20,000,000 fully paid ordinary shares, including issue price, purpose, dates of allotment, and securities quotation information. The document is a formal announcement to the Australian Securities Exchange (ASX) regarding a new share issue and application for quotation of additional securities. It does not contain financial statements or detailed financial analysis but rather the specifics of the capital raising event and related securities information. This matches the definition of a Capital/Financing Update (CAP) filing, which covers updates on company fundraising and capital structure changes. The document length (over 14,000 characters) and detailed content confirm it is the announcement itself, not a brief notice or report publication announcement.
2009-06-03 English
Trading Halt 2 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is a market release dated 2 June 2009 from Pharmaxis Limited requesting a trading halt pending an announcement related to a capital raising. It is a short notice about a trading halt and does not contain any financial data, report content, or detailed announcement itself. The key phrase 'pending an announcement in relation to a capital raising' indicates this is a pre-announcement notice, not the actual capital raising update. According to the rules, such short notices about trading halts or pending announcements are classified as Regulatory Filings (RNS) because they are general regulatory announcements and do not fit into other specific categories like Capital/Financing Update (CAP) which would require the actual announcement details. The document length is only 1638 characters, supporting that it is a brief notice rather than a full report or update.
2009-06-01 English
US FDA Accepts Aridol New Drug Application for Review 2 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is a media release dated 14 May 2009 from Pharmaxis announcing that the U.S. FDA has accepted their New Drug Application (NDA) for review of their product Aridol. It is a public announcement about regulatory progress and product development, not a financial report, earnings release, or detailed investor presentation. The content focuses on the FDA acceptance and product information, with no financial statements or detailed financial data. The document length is about 5,073 characters, which is relatively short and consistent with a press release. There is no indication that this is an Annual Report, Interim Report, or any other detailed regulatory filing. It is not a report publication announcement since it does not mention a report being attached or published. Therefore, the best classification is Regulatory Filings (RNS), which is the fallback category for general regulatory announcements and press releases that do not fit other categories.
2009-05-13 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.